Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced the World Health Organization (WHO) had listed the Moderna COVID-19 vaccine (mRNA…
-
-
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
-
NIH announced investment of $29 million to address COVID-19 disparities
On Apr. 29, 2021, the National Institutes of Health announced it was funding $29 million in ad itional…
-
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
-
CDC | COVID-19 | Infectious Disease | Vaccine
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
-
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s…
-
COVID-19 infections survey revealed significant reductions in COVID-19 infections with single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine
On Apr. 23, 2021, University of Oxford data from the COVID-19 Infection Survey was the first to show…
-
INOVIO planned for ex-US global phase 3 trial for INO-4800
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
-
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
-
CytoDyn submitted Most Crucial Section of interim order to Health Canada for COVID-19 under rolling review
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
-
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
-
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had established a…
-
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
-
Biotechnology | Clinical Research | COVID-19 | FDA | HIV | Infectious Disease | Oncology | Therapeutics
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
-
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
-
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
-
Moderna announced clinical progress from mRNA Vaccine
On Apr. 13, 2021, Moderna announced clinical and supply updates on its COVID-19 Vaccine program. New results from…
-
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
-
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend…
-
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 9, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
-
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
-
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial is underway to determine…
-
COVID-19 | Implants | Infectious Disease | NIH | Vaccine
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
-
Biotechnology | CDC | COVID-19 | Infectious Disease | NIH | Vaccine
CDC awarded $3 billion to expand COVID-19 vaccine programs
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it has awarded funding to support…
-
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
-
Nearly 80 percent of teachers, school staff, and childcare workers received at least one shot of COVID-19 vaccine
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
-
Anixa Biosciences and OntoChem entered next stage of development for Covid-19 therapeutic
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
-
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
